Rho GTPases:: potential candidates for anticancer therapy

被引:99
作者
Aznar, S [1 ]
Fernández-Valerón, P [1 ]
Espina, C [1 ]
Lacal, JC [1 ]
机构
[1] CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, E-28029 Madrid, Spain
关键词
Rho GTPascs; human carcinogenesis; Rho effectors; Wiskott-Aldrich syndrome protein family; IQGAP; p21-activated kinase; ROCK; transcriptional regulation; apoptosis; anticancer drugs;
D O I
10.1016/j.canlet.2003.08.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Low molecular weight Rho GTPases are proteins that, in response to diverse stimuli, control key cellular processes such as cell proliferation, apoptosis, lipid metabolism, cytoarchitecture, adhesion, migration, cell polarity, and transcriptional regulation. The high incidence of overexpression of some members of the Rho family of GTPases in human tumors suggests that these proteins are important in the carcinogenic process, and therefore potential candidates for a therapeutic intervention. In recent years, the characterization of downstream effectors to Rho GTPases has increased our understanding of the general cellular effects that permit aberrant proliferation and motility of tumor cells. In addition, several transcription factors have been identified to play important roles at various levels of Rho-induced tumorigenesis. Accordingly, drugs that specifically alter Rho signaling display antineoplastic properties both at the level of tumor growth and tumor metastasis. In this review, a brief summary of the progress made in understanding the biological functions elicited by Rho GTPases that contribute to tumor biology will be made. In addition, a description of new drugs available targeted to specific elements of Rho signaling with antineoplastic or antimetastatic activity is included. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:181 / 191
页数:11
相关论文
共 50 条
  • [41] Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates
    Xiao, Zhiyan
    Morris-Natschke, Susan L.
    Lee, Kuo-Hsiung
    [J]. MEDICINAL RESEARCH REVIEWS, 2016, 36 (01) : 32 - 91
  • [42] FoxM1 inhibitors as potential anticancer drugs
    Gartel, Andrei L.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (06) : 663 - 665
  • [43] Calixpyrroles: from Anion Ligands to Potential Anticancer Drugs
    Kohnke, Franz H.
    [J]. EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2020, 2020 (28) : 4261 - 4272
  • [44] Inhibition of the Eukaryotic 80S Ribosome as a Potential Anticancer Therapy: A Structural Perspective
    Pellegrino, Simone
    Terrosu, Salvatore
    Yusupova, Gulnara
    Yusupov, Marat
    [J]. CANCERS, 2021, 13 (17)
  • [45] The P53/microRNA network: A potential tumor suppressor with a role in anticancer therapy
    Sargolzaei, Javad
    Etemadi, Tahereh
    Alyasin, Atieh
    [J]. PHARMACOLOGICAL RESEARCH, 2020, 160
  • [46] A Review of Anticancer Potential of Conferone, Diversin and Ferutinin; Which One is Stronger for Cancer Therapy?
    Keshmirshekan, Fariborz
    Mohamadi-Zarch, Seyed-Mahdi
    Bagheri, Seyyed Majid
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2025, 25 (06) : 378 - 387
  • [47] Identifying and charactering novel p53 regulated genes for potential anticancer therapy
    Liu, Tan
    Laurell, Cecilia
    Selivanova, Galma
    Lundeberg, Joakim
    Nilson, Peter
    Wiman, Klas G.
    [J]. ACTA PHARMACOLOGICA SINICA, 2006, 27 : 412 - 413
  • [48] TDP-43 Depletion Induces Neuronal Cell Damage through Dysregulation of Rho Family GTPases
    Iguchi, Yohei
    Katsuno, Masahisa
    Niwa, Jun-ichi
    Yamada, Shin-ichi
    Sone, Jun
    Waza, Masahiro
    Adachi, Hiroaki
    Tanaka, Fumiaki
    Nagata, Koh-ichi
    Arimura, Nariko
    Watanabe, Takashi
    Kaibuchi, Kozo
    Sobue, Gen
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (33) : 22059 - 22066
  • [49] Peptides as Potential Anticancer Agents
    Aaghaz, Shams
    Gohel, Vivek
    Kamal, Ahmed
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (17) : 1491 - 1511
  • [50] Potential Anticancer Activity of Auranofin
    Momose, Isao
    Onodera, Takefumi
    Kawada, Manabu
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2021, 141 (03): : 315 - 321